Entrectinib
![]() |
- ₹0
- Product name: Entrectinib
- CAS: 1108743-60-7
- MF: C31H34F2N6O2
- MW: 560.64
- EINECS:
- MDL Number:MFCD28129099
- Synonyms:Entrectinib;Entrectinib(NMS-E628);N-(5-(3,5-difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide;RXDX-101;Entrectinib,NMS-E628,RXDX-101;entrecitinib;Entrectinib(RXDX-101);NMS-E628
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|
Properties
Boiling point :717.5±60.0 °C(Predicted)
Density :1.340±0.06 g/cm3(Predicted)
storage temp. :Store at -20°C
solubility :≥28.05 mg/mL in DMSO; insoluble in H2O; ≥9.82 mg/mL in EtOH with ultrasonic
form :solid
pka :12.01±0.43(Predicted)
color :Off-white to light yellow
InChIKey :HAYYBYPASCDWEQ-UHFFFAOYSA-N
SMILES :C(NC1C2=C(NN=1)C=CC(CC1=CC(F)=CC(F)=C1)=C2)(=O)C1=CC=C(N2CCN(C)CC2)C=C1NC1CCOCC1
Density :1.340±0.06 g/cm3(Predicted)
storage temp. :Store at -20°C
solubility :≥28.05 mg/mL in DMSO; insoluble in H2O; ≥9.82 mg/mL in EtOH with ultrasonic
form :solid
pka :12.01±0.43(Predicted)
color :Off-white to light yellow
InChIKey :HAYYBYPASCDWEQ-UHFFFAOYSA-N
SMILES :C(NC1C2=C(NN=1)C=CC(CC1=CC(F)=CC(F)=C1)=C2)(=O)C1=CC=C(N2CCN(C)CC2)C=C1NC1CCOCC1
Safety Information
Symbol(GHS): |
![]() |
||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Warning | ||||||||||||||||||||||||||||||
Hazard statements: |
|
||||||||||||||||||||||||||||||
Precautionary statements: |
|
Description
Entrectinib is an inhibitor of TrkA (IC50 = 1.7 nM), TrkB (IC50 = 0.1 nM), and TrkC (IC50 = 0.1 nM), as well as C-ros oncogene 1 (ROS1; IC50 = 0.2 nM) and anaplastic lymphoma kinase (ALK; IC50 = 1.6 nM). Entrectinib blocks proliferation of ALK-dependent cell lines, including those with L1196M or C1156Y resistance mutations, and inhibits ALK‐dependent signaling. It has been shown to inhibit the growth of a non-small cell lung cancer cell line bearing an EML4-ALK rearrangement. In mice bearing various Trk, ROS1, or ALK-driven xenografts, entrectinib has been shown to induce tumor regression.Related product price
- Crizotinib
₹13174.03 - Dacomitinib (PF299804)
₹5000-14200 - Regorafenib
₹6800-14800